Helicobacter pylori is a spiral-shaped bacterium that has adapted to survive in a seemingly hostile environment for microorganisms—the acidic human stomach. First described in 1981 by Barry Marshall and Robin Warren, it quickly gained notoriety as one of the most common causes of gastritis, stomach ulcers, and a risk factor for cancer.

Its shape is helical, with flagella that help it move through the gastric mucosa. It is capable of producing oxidase, catalase, and urease.

How does infection occur: invisible invasion

H. pylori is most often transmitted through the fecal-oral route or through casual contact. This can occur through contaminated water, food, unwashed hands, or even kissing. In many regions with poor sanitation, infection rates can reach 70–80%.

Most infected people experience no symptoms. However, in some cases, the bacteria trigger chronic inflammation of the stomach lining. This is a slow but persistent process that can lead to serious complications over time.

Diseases caused by this bacteria

H. pylori is directly linked to several serious diseases:

• Chronic gastritis is an inflammation of the gastric mucosa, causing pain, nausea, and loss of appetite.

• A peptic ulcer is an erosion of the wall of the stomach or duodenum.

• Gastric adenocarcinoma is one of the most dangerous forms of cancer associated with chronic infection.

• MALT lymphoma is a rare form of lymphoma that occurs in the lymphoid tissue of the stomach.

Symptoms vary, from dull abdominal pain, bloating, heartburn, and nausea to blood in the stool or vomiting. But the most frightening thing is that Helicobacter pylori can persist in the body for decades without showing any obvious symptoms.

Standard treatment no longer works?

For decades, medicine has relied on triple therapy: two antibiotics (usually clarithromycin and amoxicillin or metronidazole) combined with a proton pump inhibitor (PPI), which reduces stomach acid, creating favorable conditions for the antibiotics to work.

However, in recent years, the effectiveness of this approach has declined sharply. The main reason is antibiotic resistance. Bacteria quickly mutate and adapt to drugs. In some regions, the effectiveness of the standard regimen has fallen below 70%, a critically low figure.

Why Helicobacter pylori is out of control

The problem is exacerbated by the widespread and uncontrolled use of antibiotics. They are often prescribed without susceptibility testing, and patients frequently fail to complete treatment. This creates ideal conditions for the development of resistant strains.

The bacteria's ability to hide in the mucus layer, where it is difficult to reach with antibiotics, also plays a role. Even after apparent recovery, reinfection is possible—reinfection from either family members or the environment.

How to Prevent Infection: Simple but Effective Steps

• Wash your hands thoroughly after using the toilet and before eating.

• Drinking clean water and thermally processed food.

• Avoiding contact with other people's saliva (especially during flare-ups).

• Periodic check-ups, especially if you are prone to stomach diseases or have symptoms of discomfort.

Prevention is the key to containing the spread of this pathogenic microorganism.

Phage therapy against Helicobacter pylori: a new twist in the fight against the invisible enemy

When traditional therapy fails, phage therapy comes to the rescue. In the case of H. pylori, scientists are increasingly exploring the potential of bacteriophages. Unlike antibiotics, phages are highly specific. They target only a specific bacterial strain, sparing other intestinal microorganisms.

Several phages effective against Helicobacter pylori have already been isolated in laboratory conditions . Initial animal studies have shown a reduction in the bacterial load in the stomach without damaging the mucosa. More importantly, the development of resistance has not been observed.

Bacteriophage is our microscopic ally

The uniqueness of phages lies in their ability to replicate only in the presence of the target bacteria. This means that after completing their "mission," the virus is eliminated from the body. This approach not only minimizes side effects but also reduces the likelihood of relapse.

Furthermore, bacteriophages can be combined with conventional treatments—for example, PPIs and prebiotics—to achieve a synergistic effect. This opens the way to the development of personalized phage therapy, where each patient would receive treatment tailored to their bacterial strain.

Scientific achievements and prospects

Several research centers around the world are already working on phages against H. pylori. In particular, successes have been achieved in Japan, South Korea, and Israel.

One example is a study conducted at Seoul National University (South Korea), which tested a phage specific to H. pylori in a mouse model. A significant reduction in bacterial load and mucosal inflammation was observed. No negative impact on intestinal microflora was observed—a significant advantage over antibiotics.

In 2021, Japanese scientists published data on the development of synthetic bacteriophages based on CRISPR technology. Their phage is capable of not only destroying bacteria but also preventing their further spread within tissues. This approach paves the way for the creation of a new generation of "smart viruses."

Modern DNA sequencing technologies allow for the precise identification of Helicobacter pylori strains and the subsequent development of narrow-spectrum phages. This approach significantly increases the chances of successful treatment.

Challenges and barriers to mass use

Despite the successes, the widespread implementation of phage therapy is hindered by several factors:

• Lack of human clinical trials.

• Lack of generally accepted production and quality control standards.

• The need for official recognition of the method.

However, given the growing threat of antibiotic resistance, these difficulties are only temporary. After all, bacterial viruses may be the only hope for effectively combating Helicobacter pylori in the near future.